View in EDS PDF Full Text

The usefulness of Olanzapine plasma concentrations in monitoring treatment efficacy and metabolic disturbances in first-episode psychosis.

Saved in:
Bibliographic Details
Title: The usefulness of Olanzapine plasma concentrations in monitoring treatment efficacy and metabolic disturbances in first-episode psychosis.
Authors: Arnaiz, J. A. (AUTHOR), Rodrigues-Silva, C. (AUTHOR), Mezquida, G. (AUTHOR), Amoretti, S. (AUTHOR), Cuesta, M. J. (AUTHOR), Fraguas, D. (AUTHOR), Lobo, A. (AUTHOR), González-Pinto, A. (AUTHOR), Díaz-Caneja, M. C. (AUTHOR), Corripio, I. (AUTHOR), Vieta, E. (AUTHOR), Baeza, I. (AUTHOR), Mané, A. (AUTHOR), García-Rizo, C. (AUTHOR), Bioque, M. (AUTHOR), Saiz, J. (AUTHOR), Bernardo, M. (AUTHOR), Mas, S. (AUTHOR), PEPs group (AUTHOR), Torra, Mercè (AUTHOR)
Source: Psychopharmacology. Mar2021, Vol. 238 Issue 3, p665-676. 12p. 2 Charts, 2 Graphs.
Subjects: Metabolic disorders, Drug monitoring, Treatment effectiveness, Smoking, Valproic acid, Olanzapine
Abstract: Introduction: The role of Olanzapine therapeutic drug monitoring is controversial. The present study explores the associations of Olanzapine plasma concentrations with clinical response and metabolic side effects in first episode psychosis (FEP) after 2 months of treatment. Methods: Forty-seven patients were included. Improvement in clinical symptomatology was assessed using the PANSS. Metabolic assessment included weight, blood pressure, waist circumference, blood glucose, total cholesterol, high-density lipoprotein, low-density lipoprotein, and triglycerides. Results: The Olanzapine plasma concentrations after 2 months of treatment were positively correlated with weight gain (r = 0.49, p = 0.003), and a concentration > 23.28 ng/mL was identified as a positive predictor of weight gain (≥ 7%). The Olanzapine concentration to dose (C/D) ratio was positively correlated with the percentage of improvement in the total PANSS (r = 0.46, p = 0.004), and a C/D ratio > 2.12 was identified as a positive predictor of a good response (percentage of improvement > 30%) after 2 months of treatment. We also identified several factors that could alter Olanzapine pharmacokinetics: gender (p = 0.03), diagnosis (p = 0.05), smoking habit (p = 0.05), and co-medications such as valproic acid (p = 0.05) and anxiolytics (p = 0.01). Discussion: In conclusion, our results suggest that therapeutic drug monitoring of Olanzapine could be helpful to evaluate therapeutic efficacy and metabolic dysfunction in FEP patients treated with Olanzapine. [ABSTRACT FROM AUTHOR]
Copyright of Psychopharmacology is the property of Springer Nature and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Psychology and Behavioral Sciences Collection
FullText Links:
  – Type: pdflink
Text:
  Availability: 0
Header DbId: pbh
DbLabel: Psychology and Behavioral Sciences Collection
An: 149026260
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: The usefulness of Olanzapine plasma concentrations in monitoring treatment efficacy and metabolic disturbances in first-episode psychosis.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Arnaiz%2C+J%2E+A%2E%22">Arnaiz, J. A.</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Rodrigues-Silva%2C+C%2E%22">Rodrigues-Silva, C.</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Mezquida%2C+G%2E%22">Mezquida, G.</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Amoretti%2C+S%2E%22">Amoretti, S.</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Cuesta%2C+M%2E+J%2E%22">Cuesta, M. J.</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Fraguas%2C+D%2E%22">Fraguas, D.</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Lobo%2C+A%2E%22">Lobo, A.</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22González-Pinto%2C+A%2E%22">González-Pinto, A.</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Díaz-Caneja%2C+M%2E+C%2E%22">Díaz-Caneja, M. C.</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Corripio%2C+I%2E%22">Corripio, I.</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Vieta%2C+E%2E%22">Vieta, E.</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Baeza%2C+I%2E%22">Baeza, I.</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Mané%2C+A%2E%22">Mané, A.</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22García-Rizo%2C+C%2E%22">García-Rizo, C.</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Bioque%2C+M%2E%22">Bioque, M.</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Saiz%2C+J%2E%22">Saiz, J.</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Bernardo%2C+M%2E%22">Bernardo, M.</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Mas%2C+S%2E%22">Mas, S.</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22PEPs+group%22">PEPs group</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Torra%2C+Mercè%22">Torra, Mercè</searchLink> (AUTHOR)
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22Psychopharmacology%22">Psychopharmacology</searchLink>. Mar2021, Vol. 238 Issue 3, p665-676. 12p. 2 Charts, 2 Graphs.
– Name: Subject
  Label: Subjects
  Group: Su
  Data: <searchLink fieldCode="DE" term="%22Metabolic+disorders%22">Metabolic disorders</searchLink><br /><searchLink fieldCode="DE" term="%22Drug+monitoring%22">Drug monitoring</searchLink><br /><searchLink fieldCode="DE" term="%22Treatment+effectiveness%22">Treatment effectiveness</searchLink><br /><searchLink fieldCode="DE" term="%22Smoking%22">Smoking</searchLink><br /><searchLink fieldCode="DE" term="%22Valproic+acid%22">Valproic acid</searchLink><br /><searchLink fieldCode="DE" term="%22Olanzapine%22">Olanzapine</searchLink>
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: Introduction: The role of Olanzapine therapeutic drug monitoring is controversial. The present study explores the associations of Olanzapine plasma concentrations with clinical response and metabolic side effects in first episode psychosis (FEP) after 2 months of treatment. Methods: Forty-seven patients were included. Improvement in clinical symptomatology was assessed using the PANSS. Metabolic assessment included weight, blood pressure, waist circumference, blood glucose, total cholesterol, high-density lipoprotein, low-density lipoprotein, and triglycerides. Results: The Olanzapine plasma concentrations after 2 months of treatment were positively correlated with weight gain (r = 0.49, p = 0.003), and a concentration > 23.28 ng/mL was identified as a positive predictor of weight gain (≥ 7%). The Olanzapine concentration to dose (C/D) ratio was positively correlated with the percentage of improvement in the total PANSS (r = 0.46, p = 0.004), and a C/D ratio > 2.12 was identified as a positive predictor of a good response (percentage of improvement > 30%) after 2 months of treatment. We also identified several factors that could alter Olanzapine pharmacokinetics: gender (p = 0.03), diagnosis (p = 0.05), smoking habit (p = 0.05), and co-medications such as valproic acid (p = 0.05) and anxiolytics (p = 0.01). Discussion: In conclusion, our results suggest that therapeutic drug monitoring of Olanzapine could be helpful to evaluate therapeutic efficacy and metabolic dysfunction in FEP patients treated with Olanzapine. [ABSTRACT FROM AUTHOR]
– Name: AbstractSuppliedCopyright
  Label:
  Group: Ab
  Data: <i>Copyright of Psychopharmacology is the property of Springer Nature and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.)
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=pbh&AN=149026260
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1007/s00213-020-05715-5
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 12
        StartPage: 665
    Subjects:
      – SubjectFull: Metabolic disorders
        Type: general
      – SubjectFull: Drug monitoring
        Type: general
      – SubjectFull: Treatment effectiveness
        Type: general
      – SubjectFull: Smoking
        Type: general
      – SubjectFull: Valproic acid
        Type: general
      – SubjectFull: Olanzapine
        Type: general
    Titles:
      – TitleFull: The usefulness of Olanzapine plasma concentrations in monitoring treatment efficacy and metabolic disturbances in first-episode psychosis.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Arnaiz, J. A.
      – PersonEntity:
          Name:
            NameFull: Rodrigues-Silva, C.
      – PersonEntity:
          Name:
            NameFull: Mezquida, G.
      – PersonEntity:
          Name:
            NameFull: Amoretti, S.
      – PersonEntity:
          Name:
            NameFull: Cuesta, M. J.
      – PersonEntity:
          Name:
            NameFull: Fraguas, D.
      – PersonEntity:
          Name:
            NameFull: Lobo, A.
      – PersonEntity:
          Name:
            NameFull: González-Pinto, A.
      – PersonEntity:
          Name:
            NameFull: Díaz-Caneja, M. C.
      – PersonEntity:
          Name:
            NameFull: Corripio, I.
      – PersonEntity:
          Name:
            NameFull: Vieta, E.
      – PersonEntity:
          Name:
            NameFull: Baeza, I.
      – PersonEntity:
          Name:
            NameFull: Mané, A.
      – PersonEntity:
          Name:
            NameFull: García-Rizo, C.
      – PersonEntity:
          Name:
            NameFull: Bioque, M.
      – PersonEntity:
          Name:
            NameFull: Saiz, J.
      – PersonEntity:
          Name:
            NameFull: Bernardo, M.
      – PersonEntity:
          Name:
            NameFull: Mas, S.
      – PersonEntity:
          Name:
            NameFull: PEPs group
      – PersonEntity:
          Name:
            NameFull: Torra, Mercè
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 03
              Text: Mar2021
              Type: published
              Y: 2021
          Identifiers:
            – Type: issn-print
              Value: 00333158
          Numbering:
            – Type: volume
              Value: 238
            – Type: issue
              Value: 3
          Titles:
            – TitleFull: Psychopharmacology
              Type: main
ResultId 1